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The ethical arguments against animal experimentation remain ever-strong. In addition, the scientific case against the use of animals in research grows more compelling, with exponential progress in the development of alterna tive methods and new research technologies. The Dutch authorities recently announced an ambitious, but welcome, proposal to phase out "the use of labo ratory animals in regulatory safety testing of chemicals, food ingredients, pes ticides and (veterinary) medicines" by 2025, as well as "the use of laboratory animals for the release of biological products, such as vaccines" (Netherlands National Committee for the protection of animals used for scientific pur poses, NC ad, 2016 1 p. 3). National government departments ( e.g., the United Kingdom, UK, Home Office) have stated that alternatives to animals are now considered necessary for scientific as much as ethical reasons, also conceding that pressure exists within the research community to use animals in order to get published. Furthermore, only 20% of animal tests across the European Union (Eu) each year are conducted to meet regulatory requirements, with the vast majority carried out as basic research (including basic medical research) or breeding of genetically modified (GM) animals at academic institutions (European Commission, 2013b ) .
Despite the strength of both scientific and moral arguments, animal re search continues to increase worldwide, especially given the rising trend in use of GM animals. A Catch 22 situation also exists, with regulators largely refusing to break with tradition and continuing to accept only animal data, even when robust human-based data exists. Additionally, when new animal-free, human-relevant methods are developed, regulators often insist that research still be performed on animals; this is considered to be one of the major barri ers to achieving change and, in turn, results in an industry reluctant to invest use does not prove necessity. It is also relevant to note that from early on in a scientific career, one is discouraged from saying that experiments "didn't work" but instead, to conclude how further research or new approaches must be tried next, in light of unsuccessful or unexpected results. The use of animals has been grandfathered through, due to convention, anecdotal evidence or belief, rather than robust scientific validity. "We must use a living system" ... but it is the wrong living system and no matter how many animals are used, they will never provide an appropriate model for humans. This needs to change, par ticularly when considering the growing industry of breeding and supplying millions of GM animals worldwide each year, in repeated attempts to mimic the human condition.
The vast majority of animals are used either for basic research or breed ing of GM strains. This is clear when reviewing recent official statistics for the three highest animal-using countries in the EU; the UK, Germany, and France. For example, more than 3. 9 million procedures on animals (mice, rats, rabbits, guinea pigs, dogs, horses, cats, non-human primates, pigs, sheep, cattle, birds, xenopus, and fish, among other species) were carried out in the UK in 2016. Of these, 729,390 were genetically modified, including more than 149,000 animals deliberately bred to suffer a harmful phenotype ( a deliberately induced condi tion, such as cancer, failed immune system, or organ failure to try to simulate disease in humans). There were also increases in the number of experiments across several species, and a significant number of experiments for ingredients in household products (1700 procedures), to meet industrial chemicals legisla tion requirements, despite a policy on testing for such purposes (Home Office, 2017 ) . In fact, of the total 3. 9 million procedures conducted in the UK in 2016, only 13% were carried out for regulatory purposes. Germany bred 1. 2 million GM animals in 2015 (with similar numbers of harmful phenotype animals to the UK), representing 42% of the 2.8 million animals used annually (Federal Ministry of Food and Agriculture, 2016) 
. Figures reported for France in 2014
show that 1.8 million animals were used, however the proportion of GM ani mals was not reported (Ministry of Higher Education & Research, 2016) .
Several thousand diseases affect humans. Of these, only 500 currently have FDA-approved treatments available (National Center for Advancing Transla tional Sciences, 2017 ) . In every discipline of disease research, animals are used on an ongoing basis, yet it is continually reported that mechanisms of human conditions investigated in such animals are still not understood. This is be cause basic research in animals is a demand-driven and self-perpetuating sys tem, with much research being proposed and licensed on the basis of being repetitively performed on animals ( often termed as "well established" or "well documented" models) . Such research is neither legally required, nor does it have to be relevant or applicable to human disease to be licensed. Another key barrier to replacing animals, even when scientifically valid alternatives are available, is awareness and acceptance of their use, both by researchers and regulators (Ramirez et al., 2015) .
The first part of this chapter provides an analysis of extrapolation of ani mal studies to humans, by sampling systematic reviews carried out to assess evidence of clinical translation and incorporating a review of literature on animal toxicity studies for some well-known, established case study drugs ( e.g., paracetamol, aspirin, penicillin) and animal versus human findings. The sec ond part addresses drivers for change and the development of animal-free ( or rather, human-relevant) research methods, as well as some examples of pro cedures that do not need replacing as they can simply stop, when considering that they can logically be avoided or rejected on the basis of a correctly per formed ( and legally required) harm-benefit assessment. The chapter aims to provide an overview of the above topics and suggestions for the way forward as part of a new paradigm for a global, animal-research free future.
1

Part 1: Analysis of Abstracts from Systematic Reviews of Animal Studies
To carry out an analysis of systematic reviews on animal experiments, a re view of a sample of available literature was performed. The intention of this analysis was to provide a generally qualitative review of the literature. To do so, two separate sources were used. First, a search in PubMed (National Centre for Biotechnology Information, 2016) was made using the keyword search of "sys tematic review animal studies." This resulted in a total of 163,585 publications. PubMed allows search by Article Type and selecting this as "systematic review" further filtered results to 8,291 listings, also sorted by relevance. Second, the Google Scholar database, using the same search terms, "systematic review ani mal studies," for consistency, yielded 2,530,000 results (Google Scholar, 2016) . Dates of publications ranged from 1999-present. Generally, PubMed provided more recent listings compared to Google Scholar, which resulted in older pub lications; but this was useful to provide a greater scope for review over the past two decades as well as avoid duplication.
To account for time constraints, while still providing a reasonable sample size, the first 50 abstract listings within each source were reviewed, giving a sample total of 100 ( see Table 15 . 1 ). If a publication appeared within both sourc es, this was also accounted for, although duplicates were relatively few. Where publications were found to be not relevant, further listings were reviewed to compensate for this and to maintain a total of 100. Lee, S.H., van den Noort, M., Bosch, P. andLim, S. (2016) . Sex Differences in Acupuncture Effectiveness in Animal Models of Parkinson's Disease: A Systematic Review. BioMed Central Complementary and Alternative Medicine, 3, 16( 1 ), p. 430. Leung, M.C., Yip, K.K., Ho, Y.S., Siu, F.K., Li, W.C. and Gamer, B. (2014) . Mechanisms Underlying the Effect of Acupuncture on Cognitive Improvement: A Systematic Review of Animal Studies. journal ofNeuroimmune Pharrnacolo gy, 9(4), pp. 492-507. Li,J., Hernanda, P.Y., Bramer, W.M., Peppelenbosch, M.P., van Luijk,J. and Pan, Q. (2015) . Anti-tumor Effects of Metformin in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. PLoS One, 1; 10(6), p. eo127967. Liao, Y., Zhang, X.L., Li, L., Shen, F.M. and Zhong, M.K. (2014 McClelland,J., Bozhilova, N., Campbell, I. and Schmidt, U. (2013) Review, 21(6), McDonald]., Eng, S., Dina, 0., Schooling, C. and Terry, M. (2016) Mueller, K.F., Briel, M., Strech, D., Meerpohl,J.J., Lang, B., PubMed Motschall, E., Gloy, V., Lamontagne, F. and Bassler, D. (2014) . Dissemination Bias in Systematic Reviews of Animal Research: A Systematic Review. PLoS One, 26, 9(12), p. e116016. 24 Muhlhausler, B.S., Gibson, R.A. and Makrides, M. ( 2011 ) Muka, T., Vargas, K.G.,Jaspers, L., Wen, K.X., Dhana, K., Vitezova, PubMed A., Nano, J., Brahimaj, A., Colpani, V., Bano, A., Kraja, B., Zaciragic, A., Bramer, W.M., van Dijk, G.M., Kavousi, M. and Franco, O.H. (2016) Naumann, D., Beaven, A., Dretzke, J., Hutchings, S. and Midwinter, PubMed M. ( 2016) . Searching for the Optimal Fluid to Restore Microcirculatory Flow Dynamics after Haemorrhagic Shock: A Systematic Review of Preclinical Studies. Shock. 46(6), pp. 609-622. 27 Noorimotlagh, Z., Haghighi, N., Ahmadimoghadam, M. and PubMed Rahim, F. (2016) . An Updated Systematic Review on the Possible Effect of Nonylphenol on Male Fertility. Environmental Science and Pollution Research International, 24( 4 ), pp. 3298-3314. 28 Parker, T., Nguyen, A., Rabang,J., Patil, A and Agrawal, D.(2016) . PubMed The Danger Zone: Systematic Review of the Role of HM GB 1 Danger Signaling in Traumatic Brain Injury. Brain Injury, 7, Pot, M.W., Gonzales, V.K., Buma, P., IntHout,J., van Kuppevelt, PubMed T.H., de Vries, R.B. and Daamen, W.F. (2016) . Improved Cartilage Regeneration by Implantation of Acellular Biomaterials after Bone Marrow Stimulation: A Systematic Review and Meta-analysis of Animal Studies. Peer], 8, 4, p. e2243. 30 Qi, N., Li, W. J. and Tian, H. (2016) 111-117. 31 Raave R., de Vries, R.B., Massuger, L.F., van Kuppevelt, T.H. and PubMed Daamen, W.F. (2015) . Drug Delivery Systems for Ovarian Cancer 32 Treatment: A Systematic Review and Meta-analysis of Animal Studies. Peer], 10, 3, p. e1489. Raynor, H. A, Goff, M.R., Poole, S.A. and Chen G. (2015) . Eating Frequency, Food Intake, and Weight: A Systematic Review of Human and Animal Experimental Studies. Frontiers in Nutrition, 2(38), PubMed 33 Reis,J., Monteiro, V., de Souza, R., do Carmo, M., da Costa, G., PubMed Ribera, P. and Monteiro, M. (2016) Ting, K.H., Hill, C.L. and Whittle, S.L. ( 2015) . Quality of Reporting PubMed of Interventional Animal Studies in Rheumatology: A Systematic 44 Review Using the ARRIVE Guidelines. International]ournal of Rheumatic Diseases, 18(5), pp. 488-494. Wever, K.E., Bruintjes, M.H., Warle, M.C. and Hooijmans, C.R. (2016) . Renal Perfusion and Function During Pneumoperitoneum: A Systematic Review and Meta-analysis of Animal Studies. PLoS One, 11(9), p. eo163419.
PubMed 45 Wever, K.E., Hooijmans, C.R., Riksen, N.P., Sterenborg, T.B., Sena, PubMed E.S., Ritskes-Hoitinga, M. and Warle M.C. (2015) . Determinants of the Efficacy of Cardiac Ischemic Preconditioning: A Systematic Review and Meta-analysis of Animal Studies. PLoS One, 10( 11 ), p. eo142021. 46 Yarlagadda, S., Coca, S., Garg, A., Doshi, M., Poggio, E., Marcus, PubMed R. and Parikh, C. (2008) . Marked Variation in the Definition and 47 Diagnosis of Del ay ed Graft Function: A Systematic Review. Nephrology Dial Transplantation, 23 (9 ), pp. 2995-3003. Yen, C.C., Tu, Y.K., Chen, T.H. and Lu, H. (2014) 
. Comparison of Treatment Effects of Guided Tissue Regeneration on Infrabony Lesions Between Animal and Human Studies: A Systematic
Review and 49( 4 ), Zeng, X., Zhang, Y., Kwong,J.S., Zhang, C., Li, S., Sun, F., Niu, Y. and PubMed Du L. (2015) . Obstetrics & Gynecology, 186(4), pp. 843-849. Angst, M. and Clark, J. ( 2006) . Opioid-induced Hyperalgesia: A Qualitative Systematic Review. Anesthesiology, 104(3), pp. 570-587. Antonie, A., Sena, E., Lees, J., Wills, T., Skeers, P., Batchelor, P., Macleod, M. and Howells, D. (2013) . Stem Cell Transplanta tion in Traumatic Spinal Cord Injury: A Systematic Review and Meta-analysis of Animal Studies. Public Library of Science Biology, 11(12), p. e1001738. Bellomo, R., Ronco, C., Kellum,J., Mehta, R., Palevsky, P. and the ADQI Workgroup. (2004) Surgery, 24(2), pp. 158-168. Cave, G. and Harvey, M. ( 2009 ) 
. Intravenous lipid Emulsion As
Google Antidote Beyond Local Anesthetic Toxicity, A Systematic Review. Scholar Academic Emergency Medicine, 16(9), pp. 815-824. Corpet, D. and Pierre, F. ( 2003 ) 41(13), pp. 1911 -1922 . Dangour, A., Lock, K., Hayter, A., Aikenhead, A., Allen, E., Uauy, R. ( 2010 . Nutrition-related Health Effects of Organic Foods: A Systematic Review. American journal of Clinical Nutrition, 92( 1 ), pp. 203-210. ( 2 ), pp. 111 -120. 61 Fehlings, M. and Perrin, R. ( 2006) . Spine, 15; 31( 11 ), Giannobile, W. and Somerman, M. ( 2003 ) . Growth and Amelo-Google genin-like Factors in Periodontal Wound Healing, A Systematic Scholar Review. Annals of Periodontolo gy, 8( 1 ), pp. 193-204. 63 Gibson, C., Gray, L., Bath, P. and Murphy, S. (2008) Hasani -Ranjbar, S., Nayebi, N., Larijani, B. and Abdollahi, M. Google ( 2009 ) 
Google Scholar
RAM
. A Systematic Review of the Efficacy and Safety of Herbal Scholar
Medicines Used in the Treatment of Obesity. Wo rldjoumal of Gastroenterology, 15(25), Henderson, V., Kimmelman, J., Fergusson, D., Grimshaw, J. and Google Hackam, D. (2013) . Threats to Validity in the Design and Conduct Scholar of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments. Public Library of Science Medicine, 10(7), p. e1001489. Hooijmans, C., Leenaars, M. and Ritskes-Hoiting, M. (2010) . A Gold Standard Publication Checklist to Improve the Quality of Animal Studies, to Fully Integrate the Three Rs, and to Make Systematic Reviews More Feasible. Alternatives to Laboratory Animals, 38(2) , pp. 167-182.
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Hom, J., de Haan, R., Vermeulen, M., Luiten, P. and Limburg, M. Google ( 2001 ) . Nimodipine in Animal Model Experiments of Focal Cere-Scholar bral Ischemia: A Systematic Review. Stroke, 32( 1 o ), pp. 2433 Stroke, 32( 1 o ), pp. -2438 Houben, M., van de Beek, D., Hensen, E., de Craen, A., Rauws, E. Google and Tytgat, G. ( 1999 ) Bailey, B., Larocque, A., Notebaert, E., Sanogo, K., Chauny,J. (2010) Kwon, B., Okon, E., Hillyer,J., Mann, C., Baptiste, D., Weaver, L., Fehlings, M. and Tetzlaff, W. ( 2011 ) . A Systematic Review of Non-invasive Pharmacologic Neuroprotective Treatments for Acute Spinal Cord Injury.Journal of Neurotrauma, 28(8), pp. 1545 -1588 Lamontagne, F., Briel, M., Duffett, M., Fox-Robichaud, A., Cook, Google D., Guyatt, G., Lesur, 0. and Meade, M. (2010 ) . Systematic Review Scholar of Reviews Including Animal Studies Addressing Therapeutic Interventions for Sepsis. Critical Care Medicine, 38( 12 ), pp. 2401-2408. 76 Langenberg, C., Bagshaw, S., May, C. and Bellomo, R. (2008) . Google The Histopathology of Septic Acute Kidney Injury: A Systematic Scholar Review. Critical Care, 12(2 ), R38. 77 Lerchbaum, E. and Obermayer-Pietsch, B. (2012) . Vitamin D and Google Fertility: A Systematic Review. European journal of Endocrinology, Scholar 166, pp. 765-778. 78 Lucas, C., Criens-Poublon, L., Cockrell, C. and de Haan, R. (2002) Mapstone,]., Roberts, I. and Evans, P. (2003) . Fluid Resuscita-Google tion Strategies: A Systematic Review of Animal Trials.journal 55(3), Navas-Aden, A., Silbergeld, E., Streeter, R., Clark, J., Burke, T. and Google Eliseo Guallar, E. (2006) . Arsenic Exposure and Type 2 diabetes: Scholar A Systematic Review of the Experimental and Epidemiologic Evidence. Environmental Health Perspectives, 114(5), Pere!, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, Google P., Macleod, M., Mignini, L.,Jayaram, P. and Khan, K. (2007) . Scholar Comparison of Treatment Effects Between Animal Experiments and Clinical Trials: Systematic Review. British Medicaljoumal, 334(7586), p. 197. 82 Perlroth,J., Kuo, M., Tan,J., Bayer, A. and Miller, L. (2008 Sena, E., van der Worp, H., Bath, P., Howells, D. and Macleod, M. ( 2010 ) Shalabi, M., Gortemaker, A., Van't Hof, M.,Jansen,J. and Creugers, N. (2006) . Implant Surface Roughness and Bone Healing: A Systematic Review.Journal of Dental Research, 85(6), pp. 496-500. Subramaniam, K., Subramaniam, B. and Steinbrook, R. (2004) . Ketamine as Adjuvant Analgesic to Opioids: A Quantitative and Qualitative Systematic Review. Anaesthesia & Analgesia, 99( 2 ), W., Okon, E., S., Hill, C., Sparling, ] ., Plemel, J., Plunet, W., Tsai, E., Baptiste, D., Smithson, L., Kawaja, M., Fehlings, M. and Kwon, B. ( 2011 ) . A Systematic Review of Cellular Transplantation Therapies for Spinal Cord Injury.Journal of Neurotrauma, 28(8), pp. 1611 -1682 . Ulbrich, B. and Stahlmann, R. ( 2004 . Developmental Toxicity of Polychlorinated Biphenyls (P CBs): a Systematic Review of Experimental Data. Archives of Toxicolo gy, 78(5), pp. 252-268. van der Spoel, T., Jansen of Lorkeers, S., Agostoni, P., van Belle, E., Gyongyosi, M., Sluijter, J., Cramer, M., Doevendans, P. and Chamuleau, S. ( 2011 ) . , 0., Ahmad, N., Baile, C., Baur,J., Brown, K., Csiszar, A., Das, Google 98 99 D., Delmas, D., Gottfried, C., Lin, H., Ma, Q., Mukhopadhyay, P., Scholar Nalini, N., Pezzuto, J., Richard, T., Shukla, Y., Surh, Y., Szekeres, T., Szkudelski, T., Walle, T. and Wu,J. (2011 ) . What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol. PLoS One, 6(6), p. e19881. Wennerberg, A. and Albrektsson, T. (2009) . Effects of Titanium Surface Topography on Bone Integration: A Systematic Review. Clinical Oral Implants Research, 20(4), pp. 72-84. Wenz, H., Bartsch,J., Wolfart, S. and Kern, M. (2008) Wever, K., Menting, T., Rovers, M., van der Vliet,J., Rongen, G., Masereeuw, R., Ritskes-Hoitinga, M., Hooijmans, C. and Warle, M. (2012) . Ischemic Preconditioning in the Animal Kidney: A
Google Scholar
Systematic Review and Meta-analysis. PLoS One, 7(2), p. e32296.
Relevant abstracts were assessed overall, depending on the following information: Clear concordance between human and animal studies. Limited concordance between human and animal studies. Lack of concordance between human and animal studies, due to one of the following factors: Unclear reporting, bias, inconsistency, species differences, heterogeneity, and lack of clinical translation. It should be noted that the term concordance in this context refers to a quali tative, rather than quantitative analysis of the literature within the available timeframe. It is also important to note that the systematic reviews analyzed and the studies included within these publications (based on eligibility criteria assigned by the authors) are just a fraction of thousands of papers reviewed but rejected, some spanning four or five decades and using hundreds of thou sands of animals.
Of the 100 abstracts reviewed (50 from PubMed; 50 from Google Scholar) none stated unequivocal and conclusive concordance between animals and humans. A low proportion of abstracts ( 20%) described limited concordance Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access in specific procedures, but this was generally qualified with an advisory to in terpret the findings with caution and the need for more clinical studies to pro vide better evidence in humans. Species used in studies included rats, mice, rabbits, cats, dogs, sheep, pigs, and non-human primates, among others. A wide range of disease areas were covered, including several types of cancer, heart disease, stroke, neurological disorders ( e.g., Alzheimer's and Parkinson's disease), diabetes, bone defects and facial disorders, dental research, gene therapy and stem cell research, to provide some examples. Several publications were general reviews of how ani mal data translates to humans, as well as reviews of animal studies in specific disease areas.
The large majority of reviews ( 75%) found that assessment of human re sponse from animal data is significantly limited due to one or more of the following factors: species differences, lack of clinical translation, poor quality methodology, inconsistency, and publication bias, resulting in overstatement of the benefits of animal use in predicting human disease outcomes or safety. There was a distinct lack of evidence clinically, despite many therapies in use based on animal studies. Numerous reviews highlighted the successes claimed over basic research outcomes or new therapies in animal "models", which have, however, failed to translate to the clinic to help patients (Hirst et al., 2016) . Concerns over paucity of evidence, publication bias and consequently, over statement of benefit in translating animal data to humans have led to many systematic reviews (Briel et al., 2013) .
A key finding from this review is that, not only is publication bias very com mon in animal research, but many additional results considered unsuccess ful remain unpublished. This issue was raised in a number of the systematic reviews analyzed, for example in animal models of stroke (Sena et al., 2010 ) . Several reviews also raised concerns over animal studies and human trials be ing carried out simultaneously (Horn et al., 2001; Lucas et al., 2002 ) . Moreover, this analysis found several studies (5% of the sample reviewed), highlighting animal experiments that could have been entirely omitted and carried out di rectly and far more effectively and ethically in clinical or observational studies in humans; for example, studies on dietary intake and cardiovascular health (Reis et al., 2016; Raynor et al., 2015) , or trials of substances already in human use . In many cases, human trials were carried out in paral lel with animal experiments, representing examples of animal use that can be abandoned. This is discussed later in this chapter in more detail.
The findings from the majority of publications reviewed are consistent with other evidence on the problems of translating animal data to humans; for example, the Review of Research Using Non-human Primates (jointly commissioned in 2006 by a number of major UK research councils and chaired by Sir David Weatherall). A subsequent review in 2011 addressed one of the re commendations in the Weatherall report, to review ten years of brain research in monkeys retrospectively. Not only did the review reveal some disturbing in sights into the routine suffering of non-human primates used in neurology, but it reported the equally concerning finding that "In most cases, however, little direct evidence was available of actual medical benefit in the form of changes in clinical practice or new treatments" (Biotechnology and Biological Sciences Research Council, 2011, p. 13 Further evidence of increasing concern over the validity of animal research was highlighted in a British Medical Journal review entitled, How Pre dictive and Pro ductive is Animal Research?, which concluded that "Funds might be better directed towards clinical rather than basic research, where there is a clearer return on investment in terms of effects on patient care" ( Godlee, 2014, p. 1) . This article adds to a wealth of evidence on the poor performance of animals in predicting human responses, with an accuracy of approximately 20%-60%, depending on reviews cited (Perel et al., 2007; van Meer et al., 2012 ) .
Additionally, in a series of studies between 2013-2015, a collaboration between the Fund for the Replacement of Animals in Medical Experiments and Cruelty
Free International involved the analysis of an unprecedented level of indepen dent data from both preclinical toxicity studies and human clinical trials. The studies revealed the inadequacies of animal toxicity studies in a number of species (i.e., dog, rabbit, mouse, rat, and non-human primate) in predicting human adverse events; and the urgency for more human-relevant methods to be developed (Bailey et al., 2013 (Bailey et al., , 2014 (Bailey et al., , 2015 .
To some extent the pharmaceutical industry recognizes that the models it has been using are inadequate. There is encouraging research into alternative approaches and further consideration of the problem in some areas (Bloom berg, 2013) . In 2014, the National Institutes of Health (NIH), Tissue Chip Pro gram, began the investigation of more than 100 drugs that showed success in rodents but went on to fail in human trials (NIH, 2016) .
With regard to the purpose of experiments covered by the reviews exam ined, the majority of publications focused on basic research in animals ( 66% ). This was expected, given that this is the largest area of animal use. The re maining 34% were concerned with reviewing safety or efficacy of substances, including new and existing drugs, herbal therapies, or food related additives or substances ( e.g., low calorie sweeteners) . 
Review of Toxicity Studies in Animals, Focusing on Three Wellknown Exam p les
A follow-up literature review was performed to further address publications of toxicity tests in animals. This specific sample of the most recent literature was chosen to provide meaningful case studies on three well-known and widely used drugs worldwide: paracetamol (acetaminophen), aspirin and penicillin. Information on these studies is presented in Table 15 .2, and each drug is briefly discussed below.
2.1
Paracetamol Paracetamol was first marketed in the 195o's (Sneader, 2005) and is well known as one of the world's most common household drugs, traded under many dif ferent brand names, including Tylenol and Panadol. Despite being marketed for over five decades and the vast availability of data on global human use, paracetamol continues to be routinely tested on animals, both for "blue sky" research and attempts to market it for new purposes. Using a similar method ology to the previous review, the general key search terms of "paracetamol tox icity animals" resulted in 2,431 listings in PubMed. (Note: Using similar terms "acetaminophen toxicity animals" provided 2, 358 listings and a brief review established, as expected, that many of these were the same results).
Review of the first five listings under the above search term, published between 2014-2016, provided extensive evidence of ongoing experimental research into paracetamol in animals. For example, hepatotoxicity has been well known for decades as a risk of paracetamol overdose in humans, yet, induc ing such effects in mice is still carried out routinely, worldwide (Pingili et al., 2015) . Further recent studies show that macaques are considered a poor model due to their resistance to paracetamol poisoning when compared to humans (Yu et al., 2015) . Experimental dosing and killing of newborn mice continues (Vi berg et al., 2014) , despite paracetamol's widespread global use in children and pregnant mothers, as shown by far more directly relevant clinical or obser vational studies to check for effects on offspring (Liew et al., 2014) . Other ex perimental studies included, force feeding of GM mice with a drug to inhibit an enzyme that activates the toxic response to paracetamol in order to investigate resistance (Pu et al., 2016) , and numerous similar, experimental testing in mice (Hohmann et al., 2013) , despite much earlier, advanced human-based studies to investigate resistance to paracetamol toxicity (McCloskey et al., 1999 ) .
Another publication investigated a widely-used industrial chemical that humans are routinely exposed to in the environment via air, diet, and wa ter: aniline. The aim of the study was to investigate aniline's conversion to paracetamol, and its effects on male fe rtility. Yet, instead of employing the Yu, H., Barrass, N., Gales, S., Lenz, E., Parry, T., Powell, H., Thurman, D., Hutchison, M., Wilson, I., Bi, L., Qiao, J., Qin, Q. and Ren,J. (2015) . Metabolism by Conjugation Appears to Confer Resistance to Paracetamol (Acetaminophen) Hepatotoxicity in the Cynomolgus Monkey. Xe nobiotica, 45(3 ) , pp. 270-277.
PubMed directly relevant approach of investigating the vast amount of already avail able clinical and observational exposure data, groups of mice were injected, before being killed and dissected along with their offspring, for examination (Holm et al., 2015) .
As well as review of specific experiments on paracetamol toxicity in ani mals, further publications published between 1996 and 2012 on systematic reviews of paracetamol toxicity were analyzed ( see Table 15 .2 ). Included were reviews of translating animal models of paracetamol toxicity to humans, stating that "Considerable effort has been made to predict and model drug induced liver injury in humans using laboratory animals with only little suc cess and even some controversy" (McGill and Jaeschke, 2014, p. 10 ) . A further review of paracetamol, and similar drugs in its class, concluded that there was insufficient evidence based on animal ( and human) tests to assess toxic effects on the human kidney (Feinstein et al., 2000 ) . An analysis of clinical treatment for paracetamol-induced injury during liver surgery documented 19 different studies carried out on mice, rats, dogs, and pigs with varying results, conclud ing that evidence was insufficient to suggest the therapy was clinically relevant (Jegatheeswaran and Siriwardena, 2010 ) .
The remaining reviews focused on how paracetamol, over two decades ago ( as one of a group of "well-studied" hepatoxicants ), highlighted the need to evaluate links between in vitro and in vivo testing strategies (Huggett et al., 1996 ) ; and more recently, despite the extensive toxicity testing of paracetamol, evidence supporting its use in specific groups of patients ( e.g., the critically ill) was considered lacking (Jefferies et al., 2012) , highlighting the value of data that can only be gathered in clinical research. When taken in normal regu lar doses, paracetamol is largely considered safe in humans for a number of pain associated conditions. Ye t, it causes a wide range of toxicities in many species, for example, cancer in mice and rats (Hueper et al., 2012 ) . In fact, given Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access requirements today for extensive regulato ry toxicity testing in animals, it is highly likely that paracetamol would be denied approval based on its poor safety profile in animals.
2.2
Acetylsali cy lic Acid (Aspirin)
Acetylsalicylic acid, commonly known as Aspirin, has been in human use for more than a century. It is still considered successful; and given its relatively cheap production costs and widespread use for a number of indications, it is still considered a "blockbuster" drug in terms of revenue (Hartung, 2009 ). Yet, the human relevant dose of aspirin is lethal to rats and causes toxic effects in many animal species, including emb ry onic deformities in dogs, cats, mice, rats, monkeys, and rabbits (Barrow, 2002 ) . Like paracetamol, given the poor safety record of aspirin in animals, it would ve ry likely be denied approval for human use if newly marketed, according to today's regulato ry testing requirements (Hartung, 2009 ) . Aspirin continues to be routinely tested on animals, despite availability of vast libraries of both historical and new human data.
With the same methodology and sampling as the previous reviews, the search terms, "aspirin toxicity animals" were used. PubMed revealed experi ments carried out between 2012-2016, including 15-d ay oral toxicity studies of derivatives of aspirin in Wistar rats and subchronic toxicity studies in mice ( see Table 15 . 2 ). Searching for publications under the terms "acetylsalicylic acid toxicity in animals" resulted in specific studies published between 2000-2013. These included administration of large doses to pregnant rabbits, concluding that aspirin is not teratogenic to them, and highlighting inconsistencies with previous rabbit experiments and species differences with rats, having been "ex tensively studied" and exhibiting birth defects (Cappon et al., 2003) .
. 3
Pe nicillin
Alexander Fleming's pioneering work on penicillin is well known. Following this, Florey and Chain won a Nobel Prize in the 194o's for successful results in mice with penicillin; yet, they considered themselves fortunate to have chosen to test mice instead of guinea pigs, who showed lethal side effects to the drug, as Florey later remarked: "Mice were used in the initial toxicity tests because of their small size, but what a lucky chance it was, for in this respect man is like the mouse and not the guinea pig. If we had used guinea pigs extensively we should have said that penicillin was toxic and we probably should not have proceeded to t ry and overcome the difficulties of producing the substance for trial in man" (Florey, 1953, p. 12 ) .
In fact, penicillin is safe, to some extent, in mice and rats but has severe, often lethal, effects in hamsters and guinea pigs due to their ve ry sensitive intestinal microbiota, making them particularly susceptible when compared to other species. Animal users are quick to respond to this issue, stating that multiple species are used to assess the most appropriate "model" for humans and account for differences (heterogeneity) in animals. Again, no dispute is made on this; indeed, this has been the tenet in toxicology for decades, testing in different species and varying doses, modifying their condition either geneti cally, chemically or physically in an attempt to elicit the reaction needed. Yet, the high attrition rate of new pharmaceuticals and lack of progress in key areas of disease research should suggest that something is wrong. The use of animals is the only area of scientific research where the same dated techniques are still being used 60-70 years later, despite their limitations being well known. No other area of science continues to use such a dogmatic approach. As evi dence of this, a general literature review of the search terms "penicillin tox icity animals" results in numerous publications over decades, several of the most recent listings (2011-2016, see Table 15 . 2) involving rats, rabbits, and other animals; even using penicillin in repeated experiments to induce effects, in cluding anxiety and depression ( to try to mimic effects in rats already seen in patients), weight loss, organ failure, and deliberate epilepsy to test the effects of other drugs that, like penicillin, are already in extensive global use, with a wealth of clinical toxicity data available.
Part 2: Drivers for Change-Development of Animal-free Te sting Methods
It should be noted that use of the term altern atives in this chapter refers only to methods that replace the use of animals and their tissues. It is necessary to make this distinction, given the widely-used terminology of the 3Rs ( replace ment, reduction and refinement), first proposed in The Principles of Hum ane Exp erim ental Techniq ue (Russell and Burch, 1959 ) . The ultimate goal of Russell and Burch in establishing the 3Rs was replacement. While measures to refine methods or reduce animal numbers are, of course, to be encouraged, much at tention is devoted to these 2Rs and, to some extent, it has diverted focus from replacement. Given six decades of the 3R principles, dedicated attention to replacement is long overdue. This is also reflected in European Directive 2010/63/EU on animals used for scientific purposes (European Parliament, 2010, p. 2 ) , which states that it "represents an important step towards achieving the final goal of full replacement of procedures on live animals for scientific and educational purposes as soon as it is scientifically possible to do so. To that end, it seeks to Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access facilitate and promote the advancement of alternative approaches." Although the Directive was implemented in January 2013, there has been relatively little decrease and, in many cases, an increase in animal use across individual Mem ber States. Therefore, there is still great scope for improvement, particularly with regard to funding the development, acceptance, and adoption of animal free, human-based methods. Furthermore, the broad interpretation of the term altern atives under the auspices of the 3Rs is used to describe the use of some animals as "alternatives" to others, for example the use of zebrafish over rodents (Charles River, 2016) ; transgenic mice to "replace" non-human primates (Home Office, 2014) ; and even the use of minipigs, instead of dogs, as an "alternative" that m ay be more acceptable to the public, because they are considered "food animals" (Forster et al., 2010 ) . Aside from the poor ethical argument, replacing one animal with another still fails to address the wro ng model problem.
Use of public opinion and political lobbying to drive legislative change remains vital to fueling research and developments in animal-free science. The clearest example in recent years is the phased-in bans on animal-tested cosmetics across the EU between 2009 -2013 (European Commission, 2013 . A testing ban on cosmetic ingredients was enforced from March 11, 2009, along with a partial marketing ban for 10 animal-test requirements. This was even tually followed by a further marketing ban from March 11, 2013 for endpoints considered more complex (i.e., repeat dose toxicity, skin sensitization, repro ductive toxicity, carcinogenicity, and toxicokinetics). However, for safety data requirements of cosmetic substances, some of these endpoints are rarely or not required (Noh yn ek et al., 2010 ) . Despite delays in implementing the bans and legal challenges attempting to abolish them altogether, they had a monumen tal effect on the industry, with the development of numerous in vitro methods to be ready in time. Despite loopholes with conflicting chemicals safety-testing legislation, such as Registration, Evaluation, Authorisation and Restriction of CHemicals (REACH) (European Chemicals Agency, 2007) , the bans have been responsible for one of the most significant advances towards replacing animal tests in decades.
The campaign to end cosmetics tests on animals began in the 1970s, and it took until 1993 to see legislation amendments to mark the implementation of official EU bans. After a further two decades of del ay s, the bans were finally en forced, with significant resistance amid claims that innovation would be stifled and that the development of alternatives would not be possible. Instead, the opposite was achieved. The development of in vitro methods was stimulated to address a number of toxicological endpo ints ( the result of a study to determine how toxic a substance is). The endpoints included skin irritation, eye irritation, skin corrosion, phototoxicity, skin absorption/penetration, acute toxicity, and genotoxicity/mutagenicity. In preparation for the forthcoming bans, around 30 new in vitro assays were validated by 2007 (Hartung, 2008) , with more developed since and projections that the in vitro toxicity testing market will be worth us$17,227 million by 2018 (PR Newswire, 2014) . The bans have also affected positive change outside EU borders, with similar bans now in place in India, Israel, Norway, and New Zealand, as well as partial or full enforcements in many other countries.
Methods Now Available, Previously Considered Only Possible in Animals-Some Examples
Replacement can be ( and is being) achieved by a number of approaches, in cluding in vitro and in silica models. Some examples are discussed below. In its 2014 Delivery Plan, Working to reduce the use of animals in scientific research, the UK Home Office devoted much of the text to supporting the con tinuance of animal research. However, the plan also showcases human in vitro methods, for example, using induced pluripotent stem cells (Yu sa et al., 2011) , which it describes as "work that in the past could only have been modelled in animal systems" (Home Office, 2014, p. 16) .
Scientists at the University of Newcastle have developed human skin-based assays, using cells isolated from the blood sample of healthy volunteers to as sess new drugs, cosmetics and household products. The technology, now mar keted as Skimune by Alcyomics Ltd, could have predicted the adverse effects seen in the volunteers of the TGN1412 monoclonal antibody clinical trial in 2006 (Alcyomics, 2017 .
Other high performance initiatives include physiologically-based pharma cokinetic modelling (PBPK), which quantitatively predicts the characteristics of substances in the body ( e.g., blood flow or effects on organs). The introduc tion of in vitro PBPK models over the past two decades is credited with re ducing drug failure rates from over 40% to under 10% (McKim, 2010 ) . Another major area of replacement research uses devices, known as Multi Organ Chips (MOC), to mimic the human body's response to chemicals and disease pro cesses, with the ultimate goal being a human on a chip. Over the past few years, advances in MOC technology have been exponential. For example, the organ on a chip devices developed at Harvard's Wyss Institute can mimic events in tissue function and disease, such as air flow, bacterial infection, immune sys tem response, blood clotting, fluid leakage and, most recently, electrical activ ity across cells, to predict safety and disease mechanisms in patients (Wyss Institute, 2017 ) . For further discussion see Wilkinson, 2019, Chapter 26. At the United States NIH Chemical Genomics Centre, a major testing pro gram has been underway since 2004, involving a robotic-arm system that tests thousands of chemicals, using patient donated cells. The high throughput system performs approximately 3 million tests per week in relation to a differ ent disease. The success of the system ( also funded under the To xico lo gy in the 21st Century, ToX 21, initiative) in screening and identifying suitable candidate drugs has dramatically saved time, cost, and resources, resulting in human clinical trials starting within a year.
A further groundbreaking concept is the Adverse Outcome Pathway (AOP ), a key component of the paradigm shift towards human-relevant methods and establishing a robust system for predicting human safety. An AOP is a sequence of events that starts by a chemical effect at the molecular level ( termed a Mo lecular Initiating Event) and progresses through changes ( termed Key Events) in cells, tissues, and organs to produce an adverse effect in the body. AOPs act as a bridge between emerging methods of safety testing and, ultimately, what happens in the body in response to a particular substance (xenobiotic). With increasing knowledge, AOPs can be linked to form networks, revealing adverse outcomes that share pathways and vice versa. One example is the establish ment of in vitro test methods that map the three key stages of the AOP for skin sensitization, now accepted at Organisation for Economic Co-Operation and Development (oECD) level (2015) . Before the EU cosmetic testing bans were implemented, there was a high level of skepticism over the prospect of testing substances for skin sensitization ( and other complex endpoints) without the use of animals; and while further work remains to be done, major progress has been made. The AOP program was established in 2012 and, including skin sen sitization, there are now six AOPs approved at the OECD level; five relating to human health effects and one to address potential ecotoxicological effects to wildlife (fish, birds, and amphibians) . A further 227 AOPS are in development (OECD, 2017) .
In addition to new in vitro and in silico models to address safety testing, other areas of animal use previously considered essential, such as education, have seen coordinated replacement initiatives. Although animals are still used ex tensively in this area, great successes have been achieved to date. For example, campaigns by all involved in the International Network for Humane Education (InterNICHE) project to provide training and disseminate information on hu mane methods in medicine, biology, and veterinary research ( e.g., mannequins and simulation techniques) continue to affect great change in universities and schools worldwide (InterNICHE, 2017) . Other progress is being made in edu cation as well. In 2016 1 Wa shington University announced it would end its 25year use of cats for intubation training ( the last university in the United States still using cats in this way). Instead, it will now use mannequins and advanced simulators, following significant investment in its simulation center, which made the decision possible, following sustained public awareness campaigns (Physicians Committee for Responsible Medicine, 2016) . Also in 2016, John son and Johnson subsidiary, Ethicon, finally agreed to remove live pigs from its medical-device training program, stating that it "discontinued live animal use in salestrainingacrossourNorthAmericaregion" (PeoplefortheEthicalTreatmentof Animals, 2016 ) . For further discussion see Pawlowski, et al., 2019, Chapter 22. In addition to the vast range of human-based technologies now available, another sensible approach is to improve the use of data from clinical, epide miological, and biomonitoring studies. All of these have been considerably underused to date and could not only improve patient-safety and disease research but avoid the unnecessary use of animals.
Abandonment of Redundant and Duplicative Animal Te sts
The ethical arguments concerning use of animals and problems with scien tific validity are compounded further by the issue of duplicative experiments, which is a widespread problem. Many of the same tests are carried out over and over again, often amid claims of needing to maintain confidentiality and preserving intellectual property, despite mandates to share data. One example, a robust analysis of safety data submitted under the REACH program, recently revealed that, incredibl y, the Draize eye irritation test had been carried out on rabbits for two chemicals, 90 times per substance. (Luechtefeld et al., 2016) . Not all tests need replacing. Many can end now as they are out of date or have been found to be redundant. A recent case is the deletion of the single dose toxicity test from the European Medicines Agency guidelines, after it was recognized that information from the test could be obtained elsewhere, and that the test was of limited value (European Medicines Agency, 2010 ) . Further more, there are many examples of animal tests that require a root and branch analysis and retrospective assessment to not only assess whether scientif ic objectives were met but also whether such procedures should have been approved at all. A case study to demonstrate this further is the European Coali tion to End Animal Experiments (EC EAE ). In 2014, ECEAE estimated that its strategy of toxicological review and comment on animal testing proposals for chemicals registered under the REAC H legislation saved at least 18,000 animals, through rejected and withdrawn proposals. This was achieved on the basis of existing data or evidence that the tests proposed were unnecessary or unjusti fied (ECEAE, 2014) . Another recent example is the welcome decision that the year-long chronic-toxicity test for pesticides is no longer required in dogs, on the basis that it is not scientifically justified (Kobel et al., 2010 ) . The test has been dropped in the EU, the United States, and Canada. Although there are still requirements for the one-year test to be carried out in other countries, the restrictions mark a change in attitudes and a meaningful review of testing requirements. The campaign continues to see the test abolished worldwide as soon as possible.
Conclusion
The aim of this chapter was to provide a qualitative overview of evidence from systematic reviews and some individual studies of not only the flawed approach to the continued use of animals in trying to predict mechanisms of human disease; but also the success of existing and emerging animal-free methods, the opportunities for intelligent use of human-based data, and the distinction between animal tests that require replacement and those that can simply end. Advances in science, providing better technologies on an ongoing basis, should pave the way for acceptance of non-animal methods. In some areas, such as cosmetics testing, there is unprecedented change and global recog nition that animal use must end. Yet, in other areas of animal research, de spite a wealth of better science, the realities of some conventional attitudes, resistance to change, and an industry reliant on the continuation of animal experimentation ( e.g., maj or establishments funded by long-term programs of animal research, financial partnerships, GM animal breeding, commercial breeders, suppliers, and transporters of animals) mean that political lobbying, campaigning, and raising public awareness must continue to pl ay a major role. Fortunately, there are a number of animal protection, political, and scientific stakeholders who continue to work in the field, actively pushing for change, to increase recognition that animal research must end and to achieve the para digm shift that is urgently needed for humans and animals.
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